EDSA · Edesa Biotech, Inc.
$5.25
-0.41 (-7.24%)
At close · Jul 24
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions indicate the existence of a material uncertainty that may cast substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$46.68M
Shares
8.89M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2021
Net Income
-$7.19M
-16.5%
FY2025
Gross Margin
94.65%
FY2020
Operating Margin
-1946.72%
FY2020
Diluted EPS
-$3.99
-58.3%
FY2016
Operating Cash Flow
-$7.32M
-49.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | $0 | $328.8K | $0 | $211.85K | $228.29K | $1.27M | $758.69K | $372.13K | |
| — | — | — | — | $780K | $10.34M | — | — | — | — | — | — | — | |
| — | — | — | — | — | $0 | $17.6K | $0 | $133.32K | $250.04K | $818.57K | $580.82K | $662.95K | |
| — | — | — | — | — | $0 | $311.2K | $0 | $78.53K | -$21.76K | $453.12K | $177.87K | -$290.81K | |
| — | — | — | — | — | — | 94.65% | — | 37.07% | -9.53% | 35.63% | 23.44% | -78.15% | |
| $6.06M | $3.67M | $2.88M | $4.79M | $13.34M | $17.95M | $3.33M | $1.08M | $2.09M | $1.97M | $1.73M | $1.03M | $2.46M | |
| $4.96M | $4.24M | $4.13M | $4.43M | $5.04M | $5.73M | $3.38M | $543.16K | $2.76M | $2.94M | $3.32M | $3.23M | $2.87M | |
| $101.17B | $101.17B | $101.17B | $101.17B | $1.01B | — | $45.95K | — | — | — | $26.19K | $26.19K | $26.19K | |
| — | $119.27K | $186.05K | $183.47K | $118.19K | $118.79K | $57.56K | $1655 | $188K | $179.32K | $149.57K | $159.52K | $158.31K | |
| $16.01M | — | — | — | — | — | $6.73M | $1.62M | $5.29M | $5.45M | $6.18M | $5.1M | $6.09M | |
| -$11.01M | -$7.91M | -$7.01M | -$9.22M | -$18.37M | -$23.68M | -$6.4M | -$1.62M | -$5.08M | -$5.22M | -$4.91M | -$4.34M | — | |
| — | — | — | — | — | — | -1946.72% | — | -2397.11% | -2288.59% | -385.97% | -571.85% | — | |
| — | -$7.79M | -$6.83M | -$9.04M | -$18.25M | -$23.56M | -$6.34M | -$1.62M | -$4.89M | -$5.05M | -$4.76M | -$4.18M | — | |
| $6484 | — | — | — | — | — | $37.78K | $64.31K | $75.16K | $32.67K | $24.63K | $54.63K | $61.94K | |
| $569.35K | $726.84K | $845.5K | $849.14K | $822.67K | $10.34M | $37.41K | $82.09K | $40.1K | $194.7K | -$110.52K | $1.53M | -$2.69M | |
| — | — | — | — | — | — | — | — | -$20.24K | $0 | — | — | — | |
| — | -$7.18M | -$6.17M | -$8.37M | -$17.55M | -$13.34M | — | — | -$5.04M | -$5.03M | -$5.02M | -$2.81M | -$8.41M | |
| — | $800 | $800 | $800 | $800 | $800 | $800 | $0 | $800 | $800 | $7200 | $36.8K | $27.2K | |
| -$10.44M | -$7.19M | -$6.17M | -$8.37M | -$17.55M | -$13.34M | -$6.36M | -$1.54M | -$5.04M | -$5.03M | -$5.03M | -$2.84M | -$8.44M | |
| — | — | — | — | — | — | -1935.34% | — | -2378.56% | -2203.65% | -395.23% | -374.73% | -2267.88% | |
| -$10.34M | -$7.11M | -$6.2M | -$8.38M | -$17.56M | -$13.26M | -$6.31M | -$1.87M | — | — | — | — | — | |
| USD/shares | — | -$1.27 | -$1.93 | -$2.93 | — | — | — | — | — | — | -$3.99 | -$2.52 | — |
| USD/shares | — | — | — | — | — | — | — | — | — | — | -$3.99 | -$2.52 | — |
| shares | — | 5.68M | 3.2M | 2.86M | — | 1.73M | 1.23M | 462.84K | 409.91K | 208.92K | 1.26M | 1.14M | 10.83M |
| shares | — | — | — | — | — | 1.73M | 1.23M | 462.84K | 409.91K | 208.92K | 1.26M | 1.14M | 10.83M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×